The researchers retrospectively analyzed data from 209 patients with biopsy-confirmed lupus nephritis. Serum creatinine levels from diagnosis through the last follow-up were used to estimate glomerular filtration rate (eGFR). HCQ exposure was treated as a time-varying factor to assess its association with sustained declines in kidney function, defined as reductions in eGFR of 30% or 40% from baseline. Additionally, annual changes in eGFR slopes were calculated using linear mixed-effects models.
The findings were compelling and are summarized as follows:
- 33% of patients experienced a ≥30% decline in eGFR, while 23% showed a ≥40% decline during the follow-up period.
- Patients treated with HCQ demonstrated significantly better kidney outcomes compared to those not on the medication.
- HCQ use was linked to a 60% lower risk of experiencing a ≥30% eGFR decline.
- The risk of a ≥40% eGFR decline was reduced by 62% in patients receiving HCQ after adjusting for propensity scores.
- Among patients with chronic kidney disease stage 3 or higher, HCQ use was associated with a 77% decreased risk of further kidney function deterioration.
- HCQ reduced the annual eGFR decline rate by 5.12 mL/min/1.73 m² within the first five years of diagnosis.
- Over ten years, the annual decline in eGFR was lowered by 3.17 mL/min/1.73 m², indicating HCQ’s sustained renal protective effect.
According to the authors, these findings strongly support universal HCQ use in patients with lupus nephritis, regardless of baseline kidney function. “Our data suggest that hydroxychloroquine is not just effective in preventing flares but plays a critical role in preserving renal function early and over the long term,” they concluded.
By demonstrating that HCQ use significantly mitigates kidney function decline, this study adds to the growing body of evidence supporting its role as a cornerstone therapy in lupus nephritis management. Early initiation and sustained use of HCQ may offer a vital strategy to delay or prevent progression to end-stage kidney disease in these patients.
Reference:
Garg, S., Rovin, B., Astor, B. C., Singh, T., Hollnagel, F., Kuik, M., Kolton, L., Saric, C., Lim, S. S., & Bartels, C. M. Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis. Arthritis Care & Research. https://doi.org/10.1002/acr.25616
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.